Figure 7.

Use of NOACs according to renal function. ^a110 mg BID in patients at high risk of bleeding (per SmPc). ^bOther dose reduction criteria may apply (weight ≤ 60 kg, concomitant potent P-Gp inhibitor therapy). According to EMA, SmPc edoxaban should be used in ‘high CrCl only after a careful evaluation of the individual thromboembolic and bleeding risk’.⁴⁷³ See text for details. ^c2 × 2.5 mg only if at least two out of three fulfilled: age ≥80 years, body weight ≤60 kg, creatinine ≥1.5 mg/dL (133 µmol/L). Orange arrows indicate cautionary use; see text for details. BID, twice daily; CrCl, creatinine clearance; EMA, European Medicines Agency; NOAC, non-vitamin K antagonist oral anticoagulant; RCT, randomized clinical trial; VKA, vitamin K antagonist.